arrow
A

Apurvasena Parikh

AbbVie Inc.
H指数:11
被引数:613

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The 66th ASH Annual Meeting Abstracts POSTER ABSTRACTS

第66届ASH年会摘要 海报摘要

BLOOD
IF23.1
2024-11-050
PRE
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
2024-05-164
OAAI
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Telisotuzumab Vedotin联合Nivolumab治疗NSCLC患者的1b期研究

2022-01-0122
OA
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)

Anti-PD-1抗体Budigalimab (ABBV-181) 的模型知情给药方案和I期结果

2020-12-265
OAAI